ABPI response to MHRA guidance for the end of the transition period The MHRA has published information for pharmaceutical companies preparing for the end of the Brexit transition period. The guidance provides some information on how to operate from 1 January 2021, including on licensing of medicines and devices, clinical trials, exporting active substances for […]
EU Commission Publishes Stringent New Common Specifications Requirements for Reprocessing Single-Use Devices, Making In-House Hospital Reprocessing “Difficult if not Impossible” EU Ministries of Health Face Choice: Increase Medical Waste and Cost by Using Only Original Devices or “Opt-in” to Allow Hospitals to Partner with Regulated Remanufacturers for CE Marked, Safe Reuse of Approved Single-Use Devices […]
Read More… from New EU rules for reprocessing Single-Use Devices
The EU sugar market has long been regulated by quotas which imposed limits on production of beet sugar. However, since September 30th, production and export restrictions have been lifted as part of the Common Agricultural Policy reforms. European sugar groups are now able to produce and export as much as they want. Traders have already […]
Biosimilar medicines have been the hot subject of debate for a number of years. But as health systems around the world face continued budget squeezes and seek to increase the number of patients treated with biosimilars, the use of these less expensive options becomes ever more pertinent. Today (Tuesday 15th November) patient groups from across […]
We are now living in a post-Brexit world. On the 23rd June 2016, we as a nation decided to leave the European Union and navigate our own way through this increasingly connected world. For 43 years, the UK has been a member state of the EU, working in an inter-connected market of free-trade and political collaboration, but is […]
Read More… from Brexit and the future of UK medical research